{"id":993724,"date":"2026-08-11T16:04:46","date_gmt":"2026-08-11T20:04:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/"},"modified":"2026-08-11T16:04:46","modified_gmt":"2026-08-11T20:04:46","slug":"abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/","title":{"rendered":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants<\/b><\/p>\n<p>VANCOUVER, British Columbia&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAbCellera Biologics Inc. (Nasdaq: ABCL) (\u201cAbCellera\u201d) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.<\/p>\n<p>\nAbCellera intends to use the net proceeds from the offering to fund the continued research, development and clinical advancement of its internal pipeline, including its lead clinical program, ABCL635, as well as for working capital and other general corporate purposes.<\/p>\n<p>\nJefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are acting as joint book-running managers for the proposed offering.<\/p>\n<p>\nThe securities described above are being offered pursuant to a shelf registration statement on Form S-3ASR (No. 333-285367) that was filed with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) on February 27, 2025 and automatically became effective upon filing. This proposed offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC\u2019s website located at www.sec.gov. Copies of the preliminary prospectus supplement and an accompanying prospectus related to the proposed offering may also be obtained, when available, from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; J.P. Morgan Securities LLC, c\/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Cantor Fitzgerald &amp; Co., Attention: Capital Markets, 110 East 59<sup>th<\/sup> Street, 6<sup>th<\/sup> Floor, New York, NY 10022, or by email at prospectus@cantor.com; UBS Securities LLC, Attention: Prospectus Department, 11 Madison Avenue, New York, NY 10010, by email at ol-prospectus-request@ubs.com; or BMO Capital Markets Corp., Attn: Equity Syndicate Department, 151 W 42nd Street, 32nd Floor, New York, NY 10036, or by email at bmoprospectus@bmo.com.<\/p>\n<p>\nNo securities are being offered or sold, directly or indirectly, in Canada or to any resident of Canada.<\/p>\n<p>\nThis press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.<\/p>\n<p><b>About AbCellera Biologics Inc.<\/b><\/p>\n<p>\nAbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in the areas of endocrinology, women\u2019s health, immunology, oncology, and more.<\/p>\n<p><b>AbCellera Forward-looking Statements<\/b><\/p>\n<p>\nThis document contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management\u2019s beliefs and assumptions and on information currently available to management. All statements contained in this document other than statements of historical fact are forward-looking statements, including statements regarding the size and expected proceeds from the proposed offering, completion and timing of the proposed offering, and the anticipated use of proceeds from the proposed offering. In some cases, you can identify forward-looking statements by the words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.<\/p>\n<p>\nThese statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties, other factors, and definition of our business metrics are described under \u201cRisk Factors,\u201d \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d and elsewhere in the documents we file with the SEC from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this document represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260811173370\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260811173370\/en\/<\/a><\/span><\/p>\n<p><b>Inquiries<br \/>\n<\/b><br \/>Media: Tiffany Chiu; media@abcellera.com, +1(236)521-6774<br \/>\n<br \/>Partnering: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005<br \/>\n<br \/>Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116<\/p>\n<p><b>KEYWORDS:<\/b> North America Canada<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Other Health Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260811173370\/en\/705128\/3\/AbCellera_Full_Colour_RGB_1.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; AbCellera Biologics Inc. (Nasdaq: ABCL) (\u201cAbCellera\u201d) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. AbCellera intends to use the net proceeds from the offering to fund the continued research, development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-993724","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; AbCellera Biologics Inc. (Nasdaq: ABCL) (\u201cAbCellera\u201d) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. AbCellera intends to use the net proceeds from the offering to fund the continued research, development &hellip; Continue reading &quot;AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T20:04:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants\",\"datePublished\":\"2026-08-11T20:04:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/\"},\"wordCount\":854,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/\",\"name\":\"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-08-11T20:04:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/","og_locale":"en_US","og_type":"article","og_title":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk","og_description":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia&#8211;(BUSINESS WIRE)&#8211; AbCellera Biologics Inc. (Nasdaq: ABCL) (\u201cAbCellera\u201d) today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares. All of the common shares and pre-funded warrants are being offered by AbCellera. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. AbCellera intends to use the net proceeds from the offering to fund the continued research, development &hellip; Continue reading \"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-11T20:04:46+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants","datePublished":"2026-08-11T20:04:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/"},"wordCount":854,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/","name":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-08-11T20:04:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260811173370r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abcellera-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/993724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=993724"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/993724\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=993724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=993724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=993724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}